Skip to main content
Top
Published in: World Journal of Surgery 2/2014

01-02-2014

“Cherry Picking”, a Multiple Non-anatomic Liver Resection Technique, as a Promising Option for Diffuse Liver Metastases in Patients with Neuroendocrine Tumours

Authors: Markus Krausch, Andreas Raffel, Martin Anlauf, Matthias Schott, Nadja Lehwald, Andreas Krieg, Stefan Andreas Topp, Kenko Cupisti, Wolfram Trudo Knoefel

Published in: World Journal of Surgery | Issue 2/2014

Login to get access

Abstract

Introduction

Liver metastases of GEP-NETs are a known major prognostic factor with a strong effect on patients’ survival. To date, various treatment options are available, whereas surgery remains the only curative option. Because large liver resections often cannot be performed due to insufficient remnant liver volume, a special operative technique, “cherry picking” (multiple nonanatomic liver resections), can be used as a tissue-preserving procedure.

Methods

Of 91 patients with various GEP-NETs, 16 patients were identified with synchronous or metachronous multifocal, bilobular liver metastases (>10). All were treated with “cherry picking.” Patient records were reviewed retrospectively and clinical data and pathology results were analyzed.

Results

Mean survival after primary tumour resection was 82.8 versus 41.2 months after liver surgery. All 16 patients are still alive. Mean recurrence-free survival after primary tumour operation was 49.8 versus 24.6 months after liver surgery. Complications of cherry picking included two postoperative biliary leakages and three small hepatic abscesses (conservative/interventional approach 25 % (n = 4), surgical approach 6.25 % (n = 1). There was no postoperative mortality. Initial hormonal symptoms (5/16 patients) completely disappeared postoperatively in 2 patients and were significantly decreased in 3 patients.

Conclusions

The tissue-preserving surgical technique “cherry picking” has developed due to improved imaging techniques and increased knowledge in liver anatomy, which has helped to make this approach safer and easier. Highly selected patients with multiple bilobular liver metastases of GEP-NET can benefit from this special surgical approach, also applicable for recurrent metastases.
Literature
1.
go back to reference Anlauf M, Gerlach P, Schott M et al (2011) Pathology of neuroendocrine neoplasms. Chirurg 82(7):567–573PubMedCrossRef Anlauf M, Gerlach P, Schott M et al (2011) Pathology of neuroendocrine neoplasms. Chirurg 82(7):567–573PubMedCrossRef
2.
go back to reference Auernhammer CJ, Goke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60(7):1009–1021PubMedCrossRef Auernhammer CJ, Goke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60(7):1009–1021PubMedCrossRef
3.
go back to reference Auernhammer CJ, Jauch KW, Hoffmann JN (2009) Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system–therapeutic strategies. Zentralbl Chir 134(5):410–417PubMedCrossRef Auernhammer CJ, Jauch KW, Hoffmann JN (2009) Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system–therapeutic strategies. Zentralbl Chir 134(5):410–417PubMedCrossRef
4.
go back to reference Bilimoria KY, Talamonti MS, Tomlinson JS et al (2008) Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 247(3):490–500PubMedCrossRef Bilimoria KY, Talamonti MS, Tomlinson JS et al (2008) Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 247(3):490–500PubMedCrossRef
5.
go back to reference Chamberlain RS, Canes D, Brown KT et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4):432–445PubMedCrossRef Chamberlain RS, Canes D, Brown KT et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4):432–445PubMedCrossRef
6.
go back to reference Chung MH, Pisegna J, Spirt M et al (2001) Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130(6):954–962PubMedCrossRef Chung MH, Pisegna J, Spirt M et al (2001) Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130(6):954–962PubMedCrossRef
7.
go back to reference de Herder WW, van Schaik E, Kwekkeboom D et al (2011) New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol (Oxf) 75(3):277–284CrossRef de Herder WW, van Schaik E, Kwekkeboom D et al (2011) New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol (Oxf) 75(3):277–284CrossRef
8.
go back to reference Ehehalt F, Saeger HD, Schmidt CM et al (2009) Neuroendocrine tumors of the pancreas. Oncologist 14(5):456–467PubMedCrossRef Ehehalt F, Saeger HD, Schmidt CM et al (2009) Neuroendocrine tumors of the pancreas. Oncologist 14(5):456–467PubMedCrossRef
9.
go back to reference Elias D, Lasser P, Ducreux M et al (2003) Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single-center prospective study. Surgery 133(4):375–382PubMedCrossRef Elias D, Lasser P, Ducreux M et al (2003) Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single-center prospective study. Surgery 133(4):375–382PubMedCrossRef
10.
go back to reference Eriksson J, Stålberg P, Nilsson A et al (2008) Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 32(5):930–938. doi:10.1007/s00268-008-9510-3 PubMedCrossRef Eriksson J, Stålberg P, Nilsson A et al (2008) Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 32(5):930–938. doi:10.​1007/​s00268-008-9510-3 PubMedCrossRef
11.
go back to reference Eriksson B, Annibale B, Bajetta E et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 90(2):214–219PubMedCrossRef Eriksson B, Annibale B, Bajetta E et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 90(2):214–219PubMedCrossRef
12.
go back to reference Frilling A, Sotiropoulos GC, Li J et al (2010) Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12(6):361–379CrossRef Frilling A, Sotiropoulos GC, Li J et al (2010) Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12(6):361–379CrossRef
13.
go back to reference Gedaly R, Daily MF, Davenport D et al (2011) Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 146(8):953–958PubMedCrossRef Gedaly R, Daily MF, Davenport D et al (2011) Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 146(8):953–958PubMedCrossRef
14.
go back to reference Glazer ES, Tseng JF, Al-Refaie W et al (2010) Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 12(6):427–433CrossRef Glazer ES, Tseng JF, Al-Refaie W et al (2010) Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 12(6):427–433CrossRef
15.
16.
go back to reference Gomez D, Malik HZ, Al-Mukthar A et al (2007) Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) 9(5):345–351CrossRef Gomez D, Malik HZ, Al-Mukthar A et al (2007) Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) 9(5):345–351CrossRef
17.
go back to reference Gurusamy KS, Ramamoorthy R, Sharma D et al (2009) Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev CD007060. doi:10.1002/14651858.CD007060 Gurusamy KS, Ramamoorthy R, Sharma D et al (2009) Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev CD007060. doi:10.​1002/​14651858.​CD007060
18.
go back to reference Gurusamy KS, Pamecha V, Sharma D et al (2009) Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev CD007118. doi:10.1002/14651858.CD007118 Gurusamy KS, Pamecha V, Sharma D et al (2009) Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev CD007118. doi:10.​1002/​14651858.​CD007118
19.
go back to reference Ho AS, Picus J, Darcy MD et al (2007) Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 188(5):1201–1207PubMedCrossRef Ho AS, Picus J, Darcy MD et al (2007) Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 188(5):1201–1207PubMedCrossRef
20.
go back to reference Hodul PJ, Strosberg JR, Kvols LK (2008) Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control 15(4):314–321PubMed Hodul PJ, Strosberg JR, Kvols LK (2008) Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control 15(4):314–321PubMed
21.
go back to reference Kianmanesh R, O’Toole D, Sauvanet A et al (2005) Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. Treatment of hepatic metastases. J Chir (Paris) 142(4):208–219CrossRef Kianmanesh R, O’Toole D, Sauvanet A et al (2005) Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. Treatment of hepatic metastases. J Chir (Paris) 142(4):208–219CrossRef
22.
go back to reference Knoefel WT, Raffel A (2011) Resection of metastases in neuroendocrine tumors: pro. Dtsch Med Wochenschr 136(17):896PubMedCrossRef Knoefel WT, Raffel A (2011) Resection of metastases in neuroendocrine tumors: pro. Dtsch Med Wochenschr 136(17):896PubMedCrossRef
23.
go back to reference Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26(13):2124–2130PubMedCrossRef Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26(13):2124–2130PubMedCrossRef
24.
go back to reference Livraghi T, Goldberg SN, Lazzaroni S et al (2000) Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 214(3):761–768PubMedCrossRef Livraghi T, Goldberg SN, Lazzaroni S et al (2000) Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 214(3):761–768PubMedCrossRef
25.
go back to reference Maire F, Hammel P, Kianmanesh R et al (2009) Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 145(1):69–75PubMedCrossRef Maire F, Hammel P, Kianmanesh R et al (2009) Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 145(1):69–75PubMedCrossRef
26.
go back to reference Massironi S, Sciola V, Peracchi M et al (2008) Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 14(35):5377–5384PubMedCrossRef Massironi S, Sciola V, Peracchi M et al (2008) Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 14(35):5377–5384PubMedCrossRef
27.
go back to reference Mayo SC, de Jong MC, Pulitano C et al (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17(12):3129–3136PubMedCrossRef Mayo SC, de Jong MC, Pulitano C et al (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17(12):3129–3136PubMedCrossRef
28.
go back to reference Mayo SC, de Jong MC, Bloomston M et al (2011) Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 18(13):3657–3665PubMedCrossRef Mayo SC, de Jong MC, Bloomston M et al (2011) Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 18(13):3657–3665PubMedCrossRef
29.
go back to reference Modlin IM, Pavel M, Kidd M, Gustafsson BI et al (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31(2):169–188PubMed Modlin IM, Pavel M, Kidd M, Gustafsson BI et al (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31(2):169–188PubMed
30.
go back to reference Norton JA, Warren RS, Kelly MG et al (2003) Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134(6):1057–1063 discussion 1063–1065PubMedCrossRef Norton JA, Warren RS, Kelly MG et al (2003) Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134(6):1057–1063 discussion 1063–1065PubMedCrossRef
31.
go back to reference Osborne DA, Zervos EE, Strosberg J et al (2006) Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13(4):572–581PubMedCrossRef Osborne DA, Zervos EE, Strosberg J et al (2006) Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13(4):572–581PubMedCrossRef
32.
go back to reference Panzuto F, Nasoni S, Falconi M et al (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12(4):1083–1092PubMedCrossRef Panzuto F, Nasoni S, Falconi M et al (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12(4):1083–1092PubMedCrossRef
33.
go back to reference Pape UF, Berndt U, Müller-Nordhorn J et al (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15(4):1083–1097PubMedCrossRef Pape UF, Berndt U, Müller-Nordhorn J et al (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15(4):1083–1097PubMedCrossRef
34.
go back to reference Pape UF, Jann H, Müller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113(2):256–265PubMedCrossRef Pape UF, Jann H, Müller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113(2):256–265PubMedCrossRef
36.
go back to reference Plöckinger U, Rindi G, Arnold R et al (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80(6):394–424PubMedCrossRef Plöckinger U, Rindi G, Arnold R et al (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80(6):394–424PubMedCrossRef
37.
go back to reference Rindi G (2010) The ENETS guidelines: the new TNM classification system. Tumori 96(5):806–809PubMed Rindi G (2010) The ENETS guidelines: the new TNM classification system. Tumori 96(5):806–809PubMed
38.
go back to reference Rindi G, Bordi C (2005) Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 19(4):519–534PubMedCrossRef Rindi G, Bordi C (2005) Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 19(4):519–534PubMedCrossRef
39.
go back to reference Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656–4663PubMedCrossRef Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656–4663PubMedCrossRef
40.
go back to reference Robertson RG, Geiger WJ, Davis NB (2006) Carcinoid tumors. Am Fam Physician 74(3):429–434PubMed Robertson RG, Geiger WJ, Davis NB (2006) Carcinoid tumors. Am Fam Physician 74(3):429–434PubMed
41.
go back to reference Sarmiento JM, Que FG, Grant CS et al (2002) Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 132(6):976–982 discussion 982–983PubMedCrossRef Sarmiento JM, Que FG, Grant CS et al (2002) Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 132(6):976–982 discussion 982–983PubMedCrossRef
42.
go back to reference Sarmiento JM, Heywood G, Rubin J et al (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197(1):29–37PubMedCrossRef Sarmiento JM, Heywood G, Rubin J et al (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197(1):29–37PubMedCrossRef
43.
go back to reference Steinmüller T, Kianmanesh R, Falconi M et al (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87(1):47–62PubMedCrossRef Steinmüller T, Kianmanesh R, Falconi M et al (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87(1):47–62PubMedCrossRef
44.
go back to reference Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 89(4):471–476PubMedCrossRef Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 89(4):471–476PubMedCrossRef
45.
go back to reference Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas 38(3):255–258PubMedCrossRef Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas 38(3):255–258PubMedCrossRef
46.
go back to reference Strosberg JR, Cheema A, Kvols LK (2011) A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 18(2):127–137PubMed Strosberg JR, Cheema A, Kvols LK (2011) A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 18(2):127–137PubMed
47.
go back to reference Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5):776–783 discussion 783–785PubMedCrossRef Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5):776–783 discussion 783–785PubMedCrossRef
48.
go back to reference Yao KA, Talamonti MS, Nemcek A et al (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130(4):677–682 discussion 682-685PubMedCrossRef Yao KA, Talamonti MS, Nemcek A et al (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130(4):677–682 discussion 682-685PubMedCrossRef
49.
go back to reference Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072PubMedCrossRef Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072PubMedCrossRef
Metadata
Title
“Cherry Picking”, a Multiple Non-anatomic Liver Resection Technique, as a Promising Option for Diffuse Liver Metastases in Patients with Neuroendocrine Tumours
Authors
Markus Krausch
Andreas Raffel
Martin Anlauf
Matthias Schott
Nadja Lehwald
Andreas Krieg
Stefan Andreas Topp
Kenko Cupisti
Wolfram Trudo Knoefel
Publication date
01-02-2014
Publisher
Springer US
Published in
World Journal of Surgery / Issue 2/2014
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-013-2267-3

Other articles of this Issue 2/2014

World Journal of Surgery 2/2014 Go to the issue